reflect continu oper sale earn growth
maintain buy rate upgrad tp
deriv estim base forward
price-to-earnings multipl adjust ep
give upsid potenti
expect top-lin revenu increas
johnson johnson report growth revenu
increas adjust ep total revenu
estim
adjust ep estim
mn except
 js stock gave return under-perform
due sever reason pharma segment sale
continu hurt impact biosimilar gener
competit sale key drug like remicad
tracleer zytiga
 also face slew lawsuit alleg person
injuri patient caus use medicin mainli
talc opioid product lawsuit result
uncertainti late california court recent order
pay decept market pelvic mesh
product surgic implant aim treat pelvic
compani nametickerjnjstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth johnson johnson| ch
incom statement
non-
return invest
per share item
balanc sheet item
product perform develop
valuat consensu perform
howev js pharmaceut product lose
steam other rise compani drug stelara
record sale y/i tremfya
report sale y/i johnson
johnson cancer drug imbruvica record sale
y/i darzalex record sale
y/i
 strong pipelin product continu
deliv grow sale keep revenu
pharmaceut segment afloat compani
current product also seek addit indic
imbruvica current phase test treatment
mantl cell lymphoma tremfya phase test
treatment pediatr psoriasi also gain fda
approv two new drug balversa spravato
wake coronaviru pandem alreadi
swept across globe big pharma compani includ
johnson johnson
scrambl respond go head head
compani other first develop
coronaviru vaccin look like compani well
way achiev goal
johnson johnson feder govern
expand research partnership relat
biomed advanc research develop
author barda support effort find
vaccin could protect peopl coronaviru
also support compani attempt develop
antivir medic could help peopl alreadi
infect diseas
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date feb last split factor new per last split date jun inform johnson johnson| ch
incom statement
non-
return invest
per share item
balanc sheet item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total revenu gross gross gener sg merger total oper oper oper expens incom incom expens net incom provis benefit incom net incom avail common net incom growth incom growth ep ep growth averag share johnson johnson| march
cash trade asset short-term total prepaid current total current net properti plant long-term defer tax long-term total non-curr total short-term account accru current portion lt tax total current long-term pension post-retir defer tax capit -other long-term total non-curr total common retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu quarterli actual annual johnson johnson| march
flow oper result net earn non-cash
expens adjust depreci amort stock-bas compens asset
write-down primarili relat alio ipr asset favor increas account payabl accru
liabil liabil
use invest activ primarili use acquisit addit properti
plant equip net purchas invest invest activ also
includ sourc proce dispos assets/busi primarili asp
proce credit support agreement
use financ activ primarili use dividend sharehold repurchas
common stock net retir short long term debt financ
activ also includ sourc proce stock option exercised/employe
withhold tax stock award financ activ
depreci amort goodwil depreci amort asset written restructur loss sale stock-bas oper chang account chang chang account chang net oper capit sale properti plant -- -- invest market equiti invest short term debt -long-term debt -- -- -total debt short term debt -long-term debt -total debt issuanc common repurchas common common prefer stock dividend financ foreign exchang rate net chang statementactu annual actual quarterli johnson johnson| march
deliv strong underli sale earn growth driven
strength busi acceler perform medic
devic busi improv profit consum busi
increas
compar
johnson johnson sale increas
compar oper sale increas
currenc neg impact point
total sale increas
compar exclud net impact acquisit
divestitur adjust oper sale growth
total sale asia-
increas
compar
total intern sale increas includ
oper growth partial off-set neg currenc impact
total sale europ declin includ
oper growth
total sale western hemispher exclud increas
includ oper growth total sale
asia-pacif africa region increas compar
includ oper growth
cog increas compar
cog sale increas compar
gross profit increas compar
gross margin compar
sg expens increas compar
sg expens sale decreas
compar
 expens increas compar
 expens sale decreas
compar
net interest expens compar net interest
expens incom expens net
compar
restructur charg compar
earn provis tax incom increas
compar earn
provis tax incom sale increas
compar
effect tax rate compar
adjust effect tax rate compar
net incom increas compar
adjust net incom decreas
compar
gaap ep increas compar
adjust ep decreas compar
compar
net incom increas
compar
johnson johnson sale increas compar
oper sale increas currenc
neg impact point net impact acquisit
divestitur world-wide sale growth neg impact
increas
compar
total sale increas compar
oper sale growth exclud net impact
acquisit divestitur adjust oper sale growth
sale increas compar
oper sale growth off-set neg
currenc impact compar
total europ sale decreas includ
oper growth off-set neg currenc impact total
sale western hemispher exclud experienc sale decreas
compar includ
oper growth off-set neg currenc impact
total sale asia-pacif africa region increas
compar includ oper growth
neg currenc impact
cog increas compar
cog sale increas compar
increas due neg impact currenc
busi well increas intang asset amort
expens intang asset amort expens
compar
total sale
decreas
compar
total sg expens decreas compar
sg expens sale decreas
compar decreas due favor
segment mix higher percentag sale come
busi plan priorit reduc brand market
expens consum busi partial off-set increas
sell market invest medic devic busi
 expens increas compar
 expens sale increas
increas due increas invest
medic devic busi relat robot digit surgeri platform along
higher up-front development mileston payment primarili
argenx collabor busi
in-process research develop expens
remain intang asset valu relat develop program
investig drug treatment respiratori syncyti
viru rsv human metapneumoviru hmpv acquir
acquisit alio biopharma inc in-process research develop
sale decreas compar
decreas
compar
compar
interest incom net compar interest expens
primarili due posit effect net invest
hedg arrang certain cross-curr swap lower averag
incom expens net compar
due addit net expens primarili
attribut litig expens relat
agreement principl settl opioid litig partial
off-set divestitur gain relat
divestitur asp busi
higher unreal gain secur
equiti step-up gain relat compani previous held equiti
invest dr ci labo
restructur charg increas compar
earn provis tax incom decreas
compar
provis tax incom decreas
compar effect tax rate
compar decreas due impact swiss tax
reform compani reassess uncertain tax posit relat
current ir audit increas unrecogn tax benefit liabil
increas annual effect tax rate posit
relat uncertain tax regard intern transfer price expens
classifi intern oper compani effect tax
net earn decreas compar
dividend paid per share compar
per share net earn per share increas
compar adjust net earn per share increas
compar
compar
increas
compar
divid major segment consum segment
total revenu
declin
world-wide revenu
beauti product
increas
increas
total revenu consum segment grew
compar includ oper growth
neg currenc impact adjust oper growth
total consum segment sale decreas
compar intern consum segment sale
increas compar
includ oper growth neg currenc impact
beauti franchis
increas
compar
total revenu consum segment increas
compar includ oper growth
neg currenc impact growth driven neutrogena
beauti product over-the-count product includ tylenol motrin
analges partial off-set lower sale babi care product
total consum segment sale increas
compar intern consum segment sale decreas
compar includ
oper growth neg currenc impact
net impact acquisit divestitur consum segment
oper sale growth posit
beauti franchis
increas
compar
total world-wide sale increas compar
oper growth partli off-set
neg impact currenc
total revenu decreas compar
revenu increas
compar oper growth
partli off-set neg currenc impact
total world-wide sale increas compar
oper growth partli off-set
neg impact currenc
total revenu decreas compar
revenu increas
compar oper growth
partli off-set neg currenc impact
growth franchis driven increment sale
acquisit ci hold co ltd dr ci labo japan well market
growth share gain neutrogena aveeno product
partli off-set divestitur roc nizor
revenu oral care
decreas
compar
revenu oral care
decreas
compar
total world-wide revenu decreas
compar oral franchis oper
declin partli off-set neg currenc
total revenu decreas compar
revenu increas
compar oper growth
partli off-set neg currenc impact
total world-wide revenu decreas compar
oral franchis oper declin
partli off-set neg currenc impact
revenu over-the-counter
franchis increas
compar
compani show growth listerin mouthwash readi tab
outsid off-set share declin retail destock
 neg impact currenc
total revenu decreas compar
revenu decreas
compar oper growth
partli off-set neg currenc impact
revenu increas
compar
total world-wide revenu increas
compar oper growth
partli off-set neg currenc impact
total revenu increas compar
revenu decreas
compar oper growth
partli off-set neg currenc impact
total world-wide revenu increas compar
oper growth partli
off-set neg currenc impact growth primarili
driven increment sale acquisit zarbe addit
contributor growth tylenol children motrin digest
health product anti-smok aid
total revenu
over-the-counter increas
compar
total revenu increas compar
revenu decreas
compar oper growth
partli off-set neg currenc impact
total world-wide revenu reduc compar
women health franchis experienc oper
growth partli off-set neg currenc impact
total revenu decreas
revenu reduc compar
oper growth total revenu
partli off-set neg currenc impact
total world-wide revenu reduc compar
includ oper growth partli
off-set neg currenc impact declin primarili driven
weak liner partial off-set strength napkin asia pacif
latin america
revenu women
reduc
compar
babi care reduc
compar
total revenu decreas compar
revenu reduc
compar oper growth partli
off-set neg impact
total world-wide revenu reduc compar
babi franchis oper growth
partli off-set neg currenc impact total
revenu decreas compar
revenu reduc
compar
total world-wide revenu reduc compar
babi franchis oper growth
partli off-set neg currenc impact
total revenu decreas compar
revenu reduc
compar
babi care reduc
compar
babi care franchis revenu declin due johnson competit
pressur coupl comparison prior year relaunch activ
total world-wide revenu increas
compar wound franchis oper
growth total revenu increas
compar revenu increas
compar
revenu wound
care reduc
compar
revenu reduc
compar
total world-wide revenu reduc compar
wound franchis oper growth
declin due divestitur compe outsid
neg currenc impact
total revenu increas compar
revenu reduc
compar
total revenu
increas
compar
total revenu increas compar
oper increas neg
currenc impact total sale increas
compar sale
increas compar
includ oper growth neg currenc impact
total revenu
increas
compar
total revenu increas compar
oper increas neg currenc
impact net impact acquisit divestitur
pharmaceut segment oper sale growth neglig growth
due stelara ustekinumab darzalex daratumumab imbruvica
trinza/trevicta paliperidon palmit erleada apalutamid
growth partial off-set biosimilar gener competit
primarili declin remicad infliximab zytiga abirateron acet
intern velcad bortezomib
total sale increas compar
sale increas
compar includ oper growth
neg currenc impact net impact acquisit
divestitur neglig
total world-wide revenu increas
compar immunolog product oper growth
partli off-set neg impact
total revenu increas compar
revenu increas
compar
total world-wide revenu increas compar
immunolog product achiev oper growth
neg impact growth due
strong uptak stelara ustekinumab tremfya guselkumab
expand indic simponi/simponi aria golimumab
immunolog market growth immunolog neg impact lower
sale remicad infliximab due increas discounts/reb
total revenu increas compar
revenu increas
compar
total world-wide revenu increas
compar oper growth
neg currenc impact
revenu
compar
revenu
compar
revenu
increas
compar
revenu stelara
 increas
compar
total revenu increas
compar total intern revenu increas
compar
total world-wide revenu increas
compar oper growth
neg currenc impact total revenu increas
compar total
intern revenu decreas compar
total world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
total world-wide revenu increas
compar oper growth
neg currenc impact total revenu increas
compar total
revenu increas compar
total world-wide revenu decreas
compar oper declin
neg currenc impact total revenu decreas
compar total
revenu decreas
compar oper declin
partli off-set total export decreas
compar
revenu
decreas
compar
revenu tremfya
increas
compar
total world-wide revenu decreas
compar oper declin
neg currenc impact total revenu decreas
compar
revenu decreas compar
oper declin partli off-set neg
currenc impact
total world-wide revenu increas
compar oper growth
partli off-set neg currenc impact total revenu
increas compar
revenu compar
total world-wide revenu increas
compar oper growth
partli off-set neg currenc impact total revenu
 increas compar
revenu compar
total world-wide revenu decreas compar
revenu
compar
cardiovascular
decreas
compar
total world-wide revenu
world-wide revenu cardiovascular decreas
compar total revenu decreas
compar total
revenu decreas compar
world-wide revenu
invokana decreas
compar
world-wide revenu cardiovascular decreas
compar total revenu decreas
compar
revenu decreas compar
world-wide revenu
xarelto increas
compar
world-wide revenu decreas
compar total revenu decreas
compar total
revenu increas compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
increas compar
world-wide revenu increas compar
world-wide revenu decreas compar
world-wide revenu decreas compar
total revenu decreas
compar total
revenu decreas compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
world-wide revenu decreas
compar total revenu decreas
compar total
revenu decreas compar
world-wide revenu
decreas
compar
revenu
decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu decreas
compar
world-wide revenu increas compar
total revenu increas
compar revenu decreas
compar oper
declin partli off-set neg currenc impact
world-wide revenu increas compar
total revenu increas
compar revenu decreas
compar oper growth
partli off-set neg currenc impact
world-wide revenu
compar
world-wide revenu
compar
world-wide revenu
increas
compar
world-wide revenu
increas
compar
world-wide revenu increas
compar total revenu decreas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu decreas
compar total revenu increas
revenu decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
world-wide revenu decreas compar
total revenu increas
compar revenu
decreas compar
world-wide revenu decreas compar
total revenu increas
compar revenu
decreas compar
world-wide revenu
decreas
compar
world-wide revenu
decreas
compar
world-wide revenu
oncolog increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu increas
compar
world-wide revenu increas compar
total revenu decreas
compar revenu increas
compar
world-wide revenu
oncolog increas
compar
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu increas
compar
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu decreas
compar
world-wide revenu decreas compar
world-wide revenu
increas
compar
world-wide revenu
decreas
compar
world-wide revenu
decreas
compar
world-wide revenu
oncolog increas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
increas compar
world-wide revenu decreas compar
total revenu decreas
compar revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu increas compar
total revenu increas
compar revenu increas
compar
world-wide revenu
decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
increas compar
world-wide revenu increas compar
total revenu increas
compar revenu increas
compar
world-wide revenu
increas
compar
world-wide revenu increas compar
total revenu decreas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu
decreas
compar
world-wide revenu
increas
compar
world-wide revenu decreas
compar total revenu decreas
compar total
revenu decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu decreas
compar total revenu decreas
compar total
revenu decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
world-wide revenu
decreas
compar
world-wide revenu
decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
increas compar
world-wide revenu
increas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
medic devic world-wide oper sale exclud net impact
acquisit divestitur grew increas due
strong perform electrophysiolog product intervent solut
busi intern energi endocutt product advanc
surgeri busi acuvu contact lens vision busi
world-wide revenu
increas
compar
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu
orthoped increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
world-wide revenu decreas compar
total revenu increas
compar revenu decreas
compar
world-wide revenu
hip increas
compar
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
decreas compar
world-wide revenu increas
compar total revenu
revenu increas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
world-wide revenu increas
compar total revenu increas
compar total
revenu increas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
decreas compar
world-wide revenu
knee increas
compar
world-wide revenu
trauma increas
compar
world-wide revenu decreas
compar revenu
decreas compar
total revenu decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
world-wide revenu decreas compar
revenu decreas
compar total revenu
decreas compar
world-wide revenu decreas compar
total revenu decreas
compar revenu decreas
compar
world-wide revenu
decreas
compar
world-wide revenu
surgeri decreas
compar
world-wide revenu
advanc increas
compar
world-wide revenu
gener decreas
compar
world-wide revenu increas compar
total revenu decreas
compar
revenu increas compar
world-wide revenu increas compar
total revenu decreas
compar revenu
increas compar
world-wide revenu decreas
compar total revenu decreas
compar total
revenu increas
compar
world-wide revenu decreas compar
total revenu increas
compar revenu
decreas compar
world-wide revenu decreas
compar total revenu decreas
compar total
revenu decreas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
decreas compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu increas compar
total revenu increas
compar revenu increas
compar
world-wide revenu
specialti decreas
compar
world-wide revenu
vision increas
compar
world-wide revenu increas
compar total revenu increas
compar total
revenu decreas
compar
world-wide revenu increas compar
total revenu increas
compar revenu
increas compar
world-wide revenu decreas compar
total revenu decreas
compar total
revenu increas
compar
world-wide revenu decreas compar
total revenu decreas
compar revenu
increas compar
world-wide revenu
increas
compar
world-wide revenu
surgic decreas
compar
 announc
agreement acquir
remain stake verb
symphoni occipito-cervico-thorac patient complex
vistas fibrin sealant manag bleed surgeri
tecni toric ii intraocular len new monofoc option
cataract patient astigmat
announc agreement acquir remain stake verb surgic inc
bortezomib thalidomid dexamethason patient newli
diagnos multipl myeloma transplant elig
stelara ustekinumab food drug fda approv
treatment adult patient moder sever activ ulcer
author combin lenalidomid dexamethason
treatment newli diagnos multipl myeloma patient
spravato esketamin nasal spray ec approv adult
european
treatment
adult patient
tremfya guselkumab submiss european medicin agenc
ema treatment adult patient activ psoriat arthriti
ebola vaccin regimen submiss ema seek licensur
investig ebola vaccin regimen prevent ebola viru
imbruvica ibrutinib submiss supplement new drug
applic fda type ii variat
combin rituximab first-lin treatment patient
chronic lymphocyt leukemia small lymphocyt lymphoma
spravato esketamin nasal spray submiss type ii variat
ema addit indic rapid reduct depress
symptom adult moderate-to-sever depress episod major
depress disord current suicid ideat intent
withdrew regulatori file extend indic opsumit
macitentan chronic thromboembol pulmonari hypertens
design treatment relaps refractori multipl myeloma
complet acquisit tari biomed llc special
develop novel drug deliveri technolog treatment
complet respons letter issu fda investig long-
complet acquisit bermekimab investig compound
multipl dermatolog indic
oper sale
expect
rang
oper expect
rang
oper sale expect rang
effect tax rate expect rang
adjust ep oper expect rang
net interest expens expect rang
deliv strong underli sale earn growth increas
driven strength busi acceler
perform medic devic busi improv profit
consum busi total sale increas
oper sale grew neg impact currenc
gaap ep increas adjust ep drop
ep increas adjust ep
drop ep increas adjust
ep increas
consum world-wide oper sale exclud net impact acquisit
divestitur grew due strong sale neutrogena
beauti product over-the-count product includ tylenol motrin
analges partial off-set lower sale babi care product
consum claim firm babi talcum powder caus develop
cancer henc compani face lawsuit due above-ment matter
well lawsuit relat opioid vagin estrogen therapi
pharmaceut world-wide oper sale exclud net impact
acquisit divestitur grew due strong perform
paliperidon palmit erleada apalutamid
medic devic world-wide sale grew due strong
perform electrophysiolog product intervent solut
busi intern energi endocutt product advanc
surgeri busi acuvu contact lens vision busi
gaap ep increas
adjust ep
drop
return asset compar return
equiti compar look toward
johnson johnson financi strength oper margin consist
past eight quarter even legal cost weigh
johnson johnson remain profit profit margin
fall time-frame
face legal risk throughout due babi talc product caus
cancer certain consum februari judg order compani
pay four women develop cancer result use
johnson johnson babi powder compani said appeal
mani lawsuit settl washington latest state go
compani role opioid epidem littl reason believ
johnson johnson legal fee end anytim soon although johnson
johnson strong enough handl advers legal challeng
return asset
compar
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
return invest
per share item
balanc sheet item
product perform develop
valuat consensu perform
y/i revenu growth ttm basi compar
oper margin compar
net margin compar
ratio mrqrevenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag marginsprofitabilityrevenu growth oper incom growthep growth johnson johnson| march
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale johnson johnson| march
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn asset johnson johnson| march
johnson johnson roe johnson
johnson roe averag oper median roe howev roe
declin due declin net margin
johnson johnson net margin net
margin due huge incom tax expens
johnson johnson asset turnov
johnson johnson leverag
leverag increas continu indic compani
use debt equiti financ asset purchas
dupont analysi johnson johnson roe healthcar sector roe
roe johnson johnson driven high net margin financi leverag
return invest capit
capit effici ratio use measur firm abil creat valu stakehold
debt equiti firm expect continu gener posit excess return new invest
futur see valu increas growth increas
johnson johnson
decreas due decreas net profit due increas incom tax expens
increas gradual
johnson johnson averag oper median johnson
 johnson higher healthcar sector johnson
johnson wacc indic compani grow effici
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom margin itemsquarterli item johnson johnson| march
balanc sheet item
outstand equival market properti plant issuanc chang johnson johnson| march
current price-to-earnings averag price-to-earnings due decreas stock price price-to-earnings
trail expect forward price-to-earnings
incom statement
non-
return invest
per share item
balanc sheet item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc street capit manag mutual automobil insur america trust new york mellon manag compani financi servic mutual fund holdersholdersharesd report outvaluevanguard total stock market etf institut fund-institut -valu mutual investor sector spdr fund-health specialized-dividend appreci johnson johnson| march
developmentsappl johnson johnson team new studi see appl watch reduc risk strokefebruari johnson collabor appl offer elig adult year older opportun join clinic studi download heartlin studi app iphon studi aim assess whether heartlin studi app iphon ecg app irregular rhythm notif featur appl watch reduc likelihood stroke improv health outcom earlier detect atrial fibril johnson johnson expand partnership depart human servic acceler discoveri potenti treatmentsfebruari johnson announc janssen compani expand exist partnership biomed advanc research develop author barda part offic assist secretari prepared respons aspr depart human servic seek treatment solut diseas caus novel coronaviru also known latest collabor enhanc janssen on-going work global partner screen librari exist antivir molecul aim identifi compound promis antivir activ announc submiss fda new darzalex daratumumab -base combin regimen patient relapsed/refractori multipl myelomafebruari janssen compani johnson johnson announc today submiss supplement biolog licens applic sbla food drug administr fda seek approv darzalex daratumumab combin kyproli carfilzomib dexamethason dkd relapsed/refractori multipl myeloma sbla support result phase candor studi compar treatment dkd carfilzomib dexamethason kd patient multipl myeloma relaps one three prior line therapi johnson johnson collabor mtv stay aliv foundat launch youth-focus edutain campaign focus tuberculosi issu indiajanuari johnson servic inc proud announc collabor intern acclaim social chang organ mtv stay aliv foundat youth-focus edutain campaign india mtv nishedh aim rais awar reduc stigma around critic health social issu face young peopl educ grant johnson johnson support inclus tuberculosi tb messag first time mtv stay aliv campaign part compani initi fight tb support govern india goal end tb johnson johnson| march
incom statement
non-
return invest
per share item
balanc sheet item
product perform develop
valuat consensu perform
consensu view analyst trend stock
forecast expect
forward price-to-earnings
lower
jnj avgfive-year growth forecast usdgrowth high day day day estim comparisonjnjindustri avg avgprice/earn yield johnson johnson| march
consensu view analyst trend stock
averag earn estim current
qtr next
qtr
sale growth estim current qtr
next qtr
averag revenu estim current
qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr surprisescurr growth rate johnson johnson| march
incom statement
non-
return invest
per share item
balanc sheet item
product perform develop
valuat consensu perform
stock price trade period averag volum trade
quarter
stock price gave total return period
stock price show huge fluctuat past dip septemb due
lawsuit file
howev stock volatil may due opioid case show upward
rang stock
stock price show huge fluctuat past dip may
stock given total return past
stock show huge fluctuat past year compani face variou lawsuit file
product although litig expens dramat fell quarter compar
massiv year earlier recommend buy rate stock tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
